Indication
Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.
Loading your page…
Loading your page…
Thyrotoxicosis;Heredodegenerative Disorders, Nervous System
Marketing Authorisation Holder: Rare Thyroid Therapeutics International AB
EMA Authorisation: 12/02/2025
INN: tiratricol
AI Drug & Interaction Analysis
Free account required
Ask Osler about Emcitate: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.